1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6350CA2F8E224717085257F7F0071C533
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-awareness-program-excellence-utilizing-advocacy-groups-social-media
18
19
203.91.157.213
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media

ID: 5408


Features:

11 Info Graphics

13 Data Graphics

130+ Metrics

8 Narratives


Pages/Slides: 31


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media"

STUDY OVERVIEW

The pharmaceutical industry uses disease state awareness campaigns to disseminate unbranded information about current trends for specific disease states to key external stakeholders.

Pharma companies often work with patient advocacy groups to inform consumers about current disease state trends and clinical programs that are in progress. Unbranded disease state Web sites are one of the principal ways that advocacy groups and pharma companies work together to provide disease awareness information.

Best Practices, LLC conducted a primary research study that examines what type of disease awareness activities companies perform with advocacy groups, when they start those activities, and which do they consider most important. The study also looks at the use of social media for disease awareness activities.


KEY TOPICS

  • Involvement of Advocacy and Legal
  • Social Media

KEY METRICS
  • From a Disease Awareness program perspective, rate the importance of the following activities related to patient advocacy groups
  • Which approaches work best to support Disease Awareness activities with Patient Advocacy groups
  • Indicate when you first use these Disease Awareness activities
  • What level of involvement does your organization's legal department take in these Disease Awareness program areas
  • When do you first use these Disease Awareness activities on social media
  • Indicate your three most heavily used social media activities
  • What was your total investment in social media Disease Awareness last fiscal year
  • Percentage that social media represents of total Disease Awareness budget


SAMPLE KEY FINDINGS

  • Patient Advocacy Groups Seen as Valuable Partners: Almost 80% of study participants think it is highly important to create alliances with patient advocacy groups. At the same time, a majority also felt it is highly important to build relationships with key advocates and work on disease awareness websites/campaigns for/with advocacy groups.
  • Supporting Activities via Advocacy Groups: Participants said the best approach for supporting disease awareness activities with patient advocacy groups were sponsoring disease state awareness events and supporting education programs.


METHODOLOGY
  • Sixteen leaders at 16 leading pharmaceutical and biotech organizations participated in this study. In addition, one global communications firm representing a biopharma client also participated.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Public Relations; Health Care; Biopharmaceutical


Companies Profiled:
Bayer; Abbvie; Genzyme; Adamas Pharmaceuticals; AstraZeneca; Biogen; Novartis; Eli Lilly; FleishmanHillard; Fresenius Medical Care AG & Co. KGaA; ZS Pharma; Indivior; Merck; Catalyst Pharmaceuticals; Prometheus Therapeutics & Diagnostics; Tokai Pharmaceuticals; Vertex Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.